BCLLatlas
Financiado
Single cell genomics to comprehensively understand healthy B cell maturation and...
Single cell genomics to comprehensively understand healthy B cell maturation and transformation to chronic lymphocytic leukemia
Unbiased analyses of the molecular make up of single cells are revolutionizing our understanding of cell differentiation and cancer. Over the last years, our groups have characterized the molecular features of normal B-cell subpop...
Unbiased analyses of the molecular make up of single cells are revolutionizing our understanding of cell differentiation and cancer. Over the last years, our groups have characterized the molecular features of normal B-cell subpopulations and of pools of leukemic cells from chronic lymphocytic leukemia (CLL), the most frequent leukemia in the Western world. These analyses have revealed that CLL subtypes are related to different B-cell maturation stages, and that they can show a complex subclonal architecture. Such subclonality is dynamically modulated during the course of the disease, and has deep implications in CLL biology, clinical aggressiveness and treatment responses. In this scenario, BCLL@las aims at deciphering the origin and molecular anatomy of CLL during the entire life history of the disease by generating genetic, transcriptional and epigenetic maps of hundred-thousands of single cells across locations, time points and individuals. We plan to fulfill four major objectives: 1) To generate a comprehensive atlas of normal B-cell maturation, 2) To understand the initial steps of neoplastic transformation through the analysis of minute B-cell monoclonal proliferations in healthy individuals, 3) To decipher the cellular diversity and clonal architecture of CLL at diagnosis, and 4) To characterize the single-cell subclonal dynamics of CLL during disease evolution and treatment response. To reach these goals, BCLL@las gathers together four teams with complementary expertise in B-cell biology, clinics and pathology of CLL, genomics, transcriptomics, epigenomics, sequencing technologies, single-cell profiling and computational biology. This, together with the richness of the available CLL samples and the technical and analytical depth of BCLL@las shall lead to unprecedented insights into the origin and evolution of cancer in the precision medicine era.
ver más
Duración del proyecto: 81 meses
Fecha Inicio: 2019-03-29
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-03-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2018-SyG:
ERC Synergy Grant
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
8M€
Líder del proyecto
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACI...
No se ha especificado una descripción o un objeto social para esta compañía.
